-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pluri to Present and Participate in Upcoming Conferences
Pluri to Present and Participate in Upcoming Conferences
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the "Company")(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming conferences.
Conference: CPHI Frankfurt
Date: November 1-3, 2022
Location: Frankfurt, Germany
Pluri's Chief Commercial Officer, Nimrod Bar Zvi, and VP Business Development, Efrat Kaduri, will attend CPHI Frankfurt.
CPHI Frankfurt brings together pharma industry participants from across the full supply chain, to source, connect, and help their businesses grow.
Conference: Jefferies London Healthcare Conference 2022
Date: November 15-17, 2022
Location: London, England
Pluri's Chief Financial Officer, Chen Franco-Yehuda will attend the conference.
The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe. The conference will feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.
Conference: Challenges and Opportunities for Mesenchymal Stem Cells
Date: November 17-19, 2022
Location: Virtual
Pluri's Chief Medical Officer, Nitsan Halevy, will be a Panelist on November 17th from 8:05 am – 8:50 am for the panel titled: What are the Current Barriers for Success?
Pluri's Chief Technology Officer, Lior Raviv, will be giving a presentation titled: Scalability of MSC Production to aid Logistical Burdens, on November 18th from 9:20am - 9:50am.
The conference's focus is—Bench to bedside: Address underserved disease areas with innovative approaches to improve regulatory outcomes, scale-up strategies, cryopreservation techniques & logistical planning.
Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at info@pluri-biotech.com
About Pluri Inc.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company's technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri's method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and biologics and aims to establish partnerships that leverage the Company's 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at or follow us on LinkedIn and Twitter.
Media Contacts
Investors: investor.relations@pluri-biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
U.S. Media: Nathan Miller at nathan@miller-ink.com / Meira Feinman at meira@miller-ink.com
HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the "Company")(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming conferences.
以色列海法,2022年10月31日(环球社)--领先的生物技术公司普鲁里公司(纳斯达克:PLUR)(多伦多证券交易所市场代码:PLUR)(以下简称“普鲁里”或“公司”)(前身为普鲁里干细胞治疗公司)今天宣布,它将参加即将举行的三个会议。
Conference: CPHI Frankfurt
Date: November 1-3, 2022
Location: Frankfurt, Germany
Pluri's Chief Commercial Officer, Nimrod Bar Zvi, and VP Business Development, Efrat Kaduri, will attend CPHI Frankfurt.
CPHI Frankfurt brings together pharma industry participants from across the full supply chain, to source, connect, and help their businesses grow.
会议:CPhI法兰克福
日期:2022年11月1日-3日
地点:德国法兰克福
普鲁里氏症Nimrod Bar Zvi首席商务官,以及Efrat Kaduri业务发展副总裁,将参加CPhI法兰克福。
CPhI法兰克福将来自整个供应链的制药行业参与者聚集在一起,以采购、联系和帮助他们的业务增长。
Conference: Jefferies London Healthcare Conference 2022
Date: November 15-17, 2022
Location: London, England
Pluri's Chief Financial Officer, Chen Franco-Yehuda will attend the conference.
The Jefferies London Healthcare Conference is the largest healthcare-dedicated conference in Europe. The conference will feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.
会议:杰富瑞伦敦医疗会议2022
日期:2022年11月15日至17日
地点:英国伦敦
普鲁里氏症首席财务官陈佛朗哥-耶胡达将出席会议.
杰富瑞伦敦医疗会议是欧洲规模最大的医疗保健会议。这次会议将有来自美洲、欧洲、中东、非洲、亚洲和澳大利亚的制药、生物技术、医疗技术和医疗保健服务行业的领先公共和私营公司参加。
Conference: Challenges and Opportunities for Mesenchymal Stem Cells
Date: November 17-19, 2022
Location: Virtual
Pluri's Chief Medical Officer, Nitsan Halevy, will be a Panelist on November 17th from 8:05 am – 8:50 am for the panel titled: What are the Current Barriers for Success?
Pluri's Chief Technology Officer, Lior Raviv, will be giving a presentation titled: Scalability of MSC Production to aid Logistical Burdens, on November 18th from 9:20am - 9:50am.
The conference's focus is—Bench to bedside: Address underserved disease areas with innovative approaches to improve regulatory outcomes, scale-up strategies, cryopreservation techniques & logistical planning.
会议:间充质干细胞面临的挑战和机遇
日期:2022年11月17日至19日
地点:虚拟
普鲁里氏症日山下首席医疗官乐青藤,将于11月17日成为小组成员这是从上午8:05到上午8:50,标题为:目前成功的障碍是什么?
普鲁里氏症Lior Raviv首席技术官,将作题为:MSC生产的可扩展性,以帮助增加后勤负担,十一月十八日这是上午9时20分至9时50分
会议的重点是从工作台到床边:用创新的方法来改善监管结果、扩大战略、冷冻保存技术和后勤规划,以解决服务不足的疾病领域。
Meetings with the Pluri team can be scheduled via the various conference partnering engines or via email at info@pluri-biotech.com
与Pluri团队的会议可以通过各种会议合作引擎或通过电子邮件INFO@PULTERI-BIOTECH.com安排
About Pluri Inc.
关于普鲁里Inc.
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company's technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri's method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine, food-tech and biologics and aims to establish partnerships that leverage the Company's 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at or follow us on LinkedIn and Twitter.
Pluri正在突破科学和工程的界限,为商业用途创造基于细胞的产品,并正在开创一场促进全球福祉和可持续发展的生物技术革命。该公司的技术平台是一种获得专利和经过验证的最先进的3D细胞扩增系统,它为从药物和气候变化到食品短缺、虐待动物等一系列倡议提供了基于细胞的新型解决方案。Pluri的方法具有独一无二的准确性、可伸缩性、成本效益以及批次之间的一致性。Pluri目前在再生医学、食品技术和生物制药领域开展业务,旨在建立合作伙伴关系,利用该公司基于3D细胞的技术,向需要有效、大规模生产细胞的其他行业提供服务。要了解更多信息,请访问我们或在LinkedIn和Twitter上关注我们。
Media Contacts
媒体联系方式s
Investors: investor.relations@pluri-biotech.com
投资者:Investor.relationship@plomi-Biotech.com
Israel Media: Shachar Yental at shacharye@gitam.co.il
以色列媒体:Shachar Yental电子邮件:shacharye@gitam.co.il
U.S. Media: Nathan Miller at nathan@miller-ink.com / Meira Feinman at meira@miller-ink.com
美国媒体:Nathan Miller电子邮件:Nathan@Miller-ink.com/Meira Feinman电子邮件:meira@Miller-ink.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧